A Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of NCR201 in the Treatment of Subjects With Parkinson's Disease

Recruiting now · Phase 1

Conditions studied: Parkinson Disease

In brief

The goal of this clinical trial is to evaluate the safety, tolerability and preliminary efficacy that NCR201 has on Parkinson's disease (PD) patients.

Key facts

Study ID

NCT06978920

Run by

Nuwacell Biotechnologies Co., Ltd.

People needed

48

Starts

2025-06-06

Expected to finish

2028-12-01

Last updated by the study team

2025-08-01

Who can join

Age: 40 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Ages between 40 and 75 years;
• Diagnosed to be Parkinson's disease according to Parkinson's disease diagnostic criteria;
• Disease history over 5 years;
• Stable dose of dopamine treatment;
• Able to undergo PET/CT/MRI detection;

You may not qualify if…

• Patients who have previously undergone brain surgery;
• Past use of stem cell therapy or participation in stem cell clinical research;
• Cognitive impairment;
• History of mental disorders;
• Patients with other serious systemic diseases;
• Past or current metastatic malignant tumors.

Where it is running

• The First Affiliated Hospital of USTC — Hefei, Anhui, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.